Genflow Biosciences PLC
GENF
Company Profile
Business description
Genflow Biosciences PLC is a preclinical biotechnology company focused on developing biological interventions aimed at tackling the effects of aging, potentially slowing or halting the aging process, and reducing the incidence of age-related diseases and thereby increasing life span. The company is also focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with age.
Contact
6 Heddon Street
LondonW1B 4BT
GBRT: +44 2081425409
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.70 | 2.00 | 0.02% |
| CAC 40 | 8,256.09 | 347.35 | 4.39% |
| DAX 40 | 23,989.33 | 1,067.74 | 4.66% |
| Dow JONES (US) | 47,625.40 | 1,040.94 | 2.23% |
| FTSE 100 | 10,606.84 | 258.05 | 2.49% |
| HKSE | 25,893.02 | 776.49 | 3.09% |
| NASDAQ | 22,538.91 | 521.06 | 2.37% |
| Nikkei 225 | 56,308.42 | 2,878.86 | 5.39% |
| NZX 50 Index | 13,253.94 | 184.28 | 1.41% |
| S&P 500 | 6,748.10 | 131.25 | 1.98% |
| S&P/ASX 200 | 8,951.80 | 21.00 | -0.23% |
| SSE Composite Index | 3,995.00 | 104.83 | 2.69% |